UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neuropathology of non-motor features of Parkinson disease

Parkinsonism & related disorders, 2009-12, Vol.15, p.S1-S5

2009

Volltextzugriff (PDF)

Early-onset familial parkinsonism due to POLG mutations

Annals of neurology, 2006-05, Vol.59 (5), p.859-862

2006

Volltextzugriff (PDF)

Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease

Acta neuropathologica, 2008-04, Vol.115 (4), p.437-444

2008

Volltextzugriff (PDF)

Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease

Movement disorders, 2008-06, Vol.23 (8), p.1085-1092

2008

Volltextzugriff (PDF)

Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?

Neurobiology of aging, 2011-05, Vol.32 (5), p.857-863

2011

Volltextzugriff (PDF)

Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy

Parkinsonism & related disorders, 2005-09, Vol.11 (6), p.381-386

2005

Volltextzugriff (PDF)

Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners

Movement disorders clinical practice (Hoboken, N.J.), 2018-07, Vol.5 (4), p.383-393

2018

Volltextzugriff (PDF)

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy

Neurology. Clinical practice, 2017-02, Vol.7 (1), p.86-93

2017

Volltextzugriff (PDF)

Brain metastases

The Neurologist (Baltimore, Md.), 2004-01, Vol.10 (1), p.31-46

2004

Volltextzugriff (PDF)

Pathological gambling caused by drugs used to treat Parkinson disease

Archives of neurology (Chicago), 2005-09, Vol.62 (9), p.1377

2005

Volltextzugriff (PDF)

Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy

Parkinsonism & related disorders, 2007-12, Vol.13 (8), p.516-519

2007

Volltextzugriff (PDF)

Duration of Benefit Per Dose: Post Hoc Analysis of “Good On” Time Per Dose for IPX203 vs CD-LD IR in the RISE-PD Phase 3 Trial (P10-11.002)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

Unilateral asterixis after thalamic hemorrhage

Neurology, 2006-01, Vol.66 (2), p.E11

2006

Volltextzugriff (PDF)

Efficacy and Safety of SEP-363856, a Non–D2-Receptor Binding Drug With Antipsychotic Activity, in Patients With Parkinson’s Disease Psychosis (2102)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Alpha-synuclein immunohistochemistry in two cases of co-occurring idiopathic Parkinson's disease and motor neuron disease

Movement disorders, 2005-11, Vol.20 (11), p.1515-1520

2005

Volltextzugriff (PDF)

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Lancet neurology, 2022-12, Vol.21 (12), p.1099-1109

2022

Volltextzugriff (PDF)

Incidental Lewy body disease and preclinical Parkinson disease

Archives of neurology (Chicago), 2008-08, Vol.65 (8), p.1074

2008

Volltextzugriff (PDF)

Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study

Parkinsonism & related disorders, 2019-07, Vol.64, p.132-137

2019

Volltextzugriff (PDF)

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study

Neurology. Clinical practice, 2023-08, Vol.13 (4), p.e200175-e200175

2023

Volltextzugriff (PDF)

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT 1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study

Neurology. Clinical practice, 2023-08, Vol.13 (4), p.e200175

2023

Volltextzugriff (PDF)

Neurologic spectrum of chronic liver failure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity

Archives of neurology (Chicago), 2005-09, Vol.62 (9), p.1385

2005

Volltextzugriff (PDF)

Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease

Archives of neurology (Chicago), 2009-09, Vol.66 (9), p.1114

2009

Volltextzugriff (PDF)

Reply to: DUOPA® is an Excellent Alternative Treatment but with Some Caveats

Movement disorders clinical practice (Hoboken, N.J.), 2019-04, Vol.6 (4), p.336-337

2019

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(48)
Bücher
(1)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Neuropathology of non-motor features of Parkinson disease

Early-onset familial parkinsonism due to POLG mutations

Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease

Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease

Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?

Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy

Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy

Brain metastases

Pathological gambling caused by drugs used to treat Parkinson disease

Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy

Duration of Benefit Per Dose: Post Hoc Analysis of “Good On” Time Per Dose for IPX203 vs CD-LD IR in the RISE-PD Phase 3 Trial (P10-11.002)

Unilateral asterixis after thalamic hemorrhage

Efficacy and Safety of SEP-363856, a Non–D2-Receptor Binding Drug With Antipsychotic Activity, in Patients With Parkinson’s Disease Psychosis (2102)

Alpha-synuclein immunohistochemistry in two cases of co-occurring idiopathic Parkinson's disease and motor neuron disease

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Incidental Lewy body disease and preclinical Parkinson disease

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial

Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT 1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study

Neurologic spectrum of chronic liver failure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity

Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease

Reply to: DUOPA® is an Excellent Alternative Treatment but with Some Caveats

Suchergebnisse filtern